Pham Quang X 4
4 · Cadrenal Therapeutics, Inc. · Filed Jun 2, 2026
Research Summary
AI-generated summary of this filing
Cadrenal (CVKD) 10% Owner Pham Quang Sells Shares
What Happened
Pham Quang, a 10% owner (trustee of The PVBQ Living Trust), sold a total of 652 Cadrenal Therapeutics (CVKD) shares in two open‑market transactions for roughly $3,075. On 2026-05-29 he sold 303 shares at a weighted average price of $5.01 (≈ $1,518). On 2026-06-02 he sold 349 shares at a weighted average price of $4.46 (≈ $1,557). These were sales (not purchases) and were executed under a prearranged Rule 10b5‑1 trading plan.
Key Details
- Transaction dates: 2026-05-29 (303 shares, weighted avg $5.00–$5.02; reported $5.01) and 2026-06-02 (349 shares, weighted avg $4.40–$4.62; reported $4.46).
- Total shares sold: 652; approximate proceeds: $3,075.
- Reporting/filing: Form 4 filed 2026-06-02 (appears timely for the reported trades).
- Ownership after transaction: Not disclosed in the provided filing excerpt.
- Notable footnotes: Sales were made pursuant to a Rule 10b5‑1 plan adopted Sept 25, 2025; weighted‑average prices reported with ranges and the reporting person will supply per‑price breakdowns on request; Pham is trustee with sole voting/dispositive power for shares held in The PVBQ Living Trust (beneficiary: his child).
Context
These are routine sales under a prearranged 10b5‑1 plan by a significant (10%) owner via a trust. The total dollar amount is small relative to typical insider trades; sales do not necessarily signal management view of the company.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-05-29$5.01/sh−303$1,518→ 181,858 total - Sale
Common Stock
[F1][F3]2026-06-02$4.46/sh−349$1,557→ 181,509 total
- 200,000(indirect: By Trust)
Common Stock
[F4]
Footnotes (4)
- [F4]Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.
- [F1]Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 through $5.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.40 through $4.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.